Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.

Ther Adv Med Oncol · 2023 · PMC10331344 · PMID 37435562

Europe PMC DOI

hedged sentence

0.7000

closest p · 14.0× alpha

0.7000

boldest claim

The sentences

did not reach statistical significancep = 0.7not close (p > 0.1)

The primary end point of median PFS nearly doubled in the SABR arm (4.4 versus 2.8 months), although this did not reach statistical significance ( p = 0.7).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.